Form D · Other Technology
Epharmix, Inc.
St. Louis, MO · CIK 0001648841
Offering snapshot reported Sep 7, 2018 · SEC filing
- Reported sold
- $1.88M Offering amount: $3M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 30, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 7, 2018 | Initial | $1,875,000 | No comparison | 6 | SEC filing |
| Sep 7, 2018 | Initial | $2,409,153 | No comparison | 11 | SEC filing |
| Jul 27, 2015 | Initial | $765,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-320889
Source: Form D, filed Sep 7, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Bakken | Director |
| Charles Bolton | Director |
| Max Bricklin | Director |
| Yiteng Huang | Director, Promoter |
| Blake Marggraff | Director, Executive, Promoter |
| Avik Som | Director, Executive, Promoter |
Issuer details
Industry: Other Technology (See others in industry)
Address:
4220 Duncan Ave Suite 201
St. Louis, MO, 63110
St. Louis, MO, 63110